Tags : : Vizient

Insights+ Key Biosimilars Events of January 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients. Hence physicians are likely to adopt biosimilars “a reference product to biologics” possessing similar […]Read More

Vizient Submits Response to the US FDA for Draft Guidance

Shots: The company submitted report for the FDA’s guidance on Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products clarifying the clinical immunogenicity study for the approval of certain proposed biosimilars and interchangeable insulin products The guidance suggests recommendations as when and whether comparative clinical immunogenicity study will be needed for insulins to support the […]Read More